HemOnc vocabulary relationships
The purpose of this page is to describe the existing relationships in the HemOnc ontology and to give examples. Most of the examples are based on adjuvant CapeOx for colon cancer, as described in the XELOXA study's primary publication (Schmoll et al. 2007, JCO).
In progress -keep checking back!
Internal relationships and examples
| Concept Type 1 | Relationship | Concept Type 2 | Example 1 | Relationship | Example 2 |
|---|---|---|---|---|---|
| Regimen | Can be followed by | Regimen | 7 plus 3i (induction) | Can be followed by | HiDAC (consolidation) |
| Regimen | Can be followed by | Procedure | FEC (neoadjuvant) | Can be followed by | Surgery |
| Regimen | Can be preceded by | Regimen | HiDAC (consolidation) | Can be preceded by | 7 plus 3i (induction) |
| Regimen | Can be preceded by | Procedure | CapeOx (adjuvant) | Can be preceded by | Surgery |
| Component | Has accepted use | Condition | Capecitabine | Has accepted use | Colon cancer |
| Regimen | Has accepted use | Condition | CapeOx | Has accepted use | Colon cancer |
| Regimen | Has antineoplastic | Component | CapeOx | Has antineoplastic | Capecitabine |
| Regimen | Has immunosuppressor | Component | Dexamethasone monotherapy | Has immunosuppressor | Dexamethasone |
| Regimen | Has immunosuppressor | Component Class | Fludarabine & Melphalan | Has immunosuppressor | ATG (type not specified) |
| Regimen | Has local therapy | Component | IT Cytarabine & Methotrexate | Has local therapy | Cytarabine |
| Regimen | Has supportive med | Component | Carboplatin & Pemetrexed | Has supportive med | Dexamethasone |
| Regimen | Has supportive med | Component Class | Bortezomib monotherapy | Has supportive med | Bisphosphonate |
| Regimen | Has been compared to | Regimen | CapeOx | Has been compared to | FULV |
| Regimen | Has been compared to | Regimen Stub | CapeOx | Has been compared to | FUFOX |
| Regimen | Has been compared to | Regimen Class | Ipilimuamb & Nivolumab | Has been compared to | Platinum doublet |
| Regimen | Has been compared to | Procedure | Cisplatin, Fluorouracil, RT | Has been compared to | Surgery |
| Component | Has brand name | Brand Name | Capecitabine | Has brand name | Xeloda |
| Regimen | Has context | Context | CapeOx | Has context | Adjuvant therapy |
| Component | Has FDA indication | Condition | Capecitabine | Has FDA indication | Colon cancer |
| Reference | Has first author | Author | XELOXA::00 | Has first author | Schmoll_Hans Joachim |
| Reference | Has middle author | Author | XELOXA::00 | Has middle author | Tabernero_Jose M |
| Reference | Has last author | Author | XELOXA::00 | Has last author | Haller_Daniel G |
| Regimen | Has modality | Modality | CapeOx | Has modality | Chemotherapy |
| Reference | Has PMID | PubMedURL | XELOXA::00 | Has PMID | https://pubmed.ncbi.nlm.nih.gov/17194911 |
| Reference | Has URL | ReferenceURL | XELOXA::00 | Has URL | https://ascopubs.org/doi/full/10.1200/jco.2006.08.1075 |
| Reference | Has title | ReferenceTitle | XELOXA::00 | Has title | Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients |
| Regimen | Is current in | Condition | CapeOx | Is current in | Colon cancer |
| Regimen | Is historical in | Condition | Edrecolomab monotherapy | Is historical in | Colon cancer |
| Component | Was FDA approved | Year | Capecitabine | Was FDA approved | 1998 |
| Reference | Was published in | Journal | XELOXA::00 | Was published in | J Clin Oncol |
| Reference | Was published year | Year | XELOXA::00 | Was published year | 2007 |
| Regimen | Has cycle | Cycle Sigs | CapeOx | Has cycle | 21-day cycle for 8 cycles |
| Study | Has reference | Reference | XELOXA | Has reference | XELOXA::00 |
| Study | Has reported endpt | Endpoint | XELOXA | Has reported endpt | OS |
| Component | Has route | Route | Capecitabine | Has route | PO |
| Study | Has study group | Study Group | ECOG E3200 | Has study group | Eastern Cooperative Oncology Group |
| Study | Has study short name | Study name short | XELOXA | Has study short name | Schmoll et al. 2007 |
| Study | Has study type | Study Class | X-ACT | Has study type | FDA registration study |
| Component | Has sig | Sig | Capecitabine | Has sig | 1000 mg/m^2 PO twice per day on days 1 to 14 |
| Component | Has sig | Sig Stub | Capecitabine | Has sig | 1660 mg/m^2/day PO on days 1 to 21 (frequency of dosing not specified) |
| Component Class | Has sig | Sig Stub | Serotonin 5-HT3 antagonist | Has sig | on the day of IV chemotherapy |
| Component | Is a | Component Class | Capecitabine | Is a | Fluoropyrimidine |
| Component Class | Is a | Component Class | Fluoropyrimidine | Is a | Pyrimidine analogue |
| Condition | Is a | Condition | Colon cancer | Is a | Colorectal cancer |
| Context | Is a | Context | Adjuvant therapy | Is a | Post-definitive therapy |
| Regimen | Is a | Regimen Class | CapeOx | Is a | Platinum doublet |
| Component | May have route | Route | Dexamethasone | May have route | PO |
| Regimen | Was studied in | Study | CapeOx | Was studied in | XELOXA |
| Context | Was studied in | Study | Adjuvant therapy | Was studied in | XELOXA |
| Condition | Was studied in | Study | Colon cancer | Was studied in | XELOXA |
External relationships and examples
| Concept Type 1 | Relationship | Concept Type 2 | Example 1 | Relationship | Example 2 |
|---|---|---|---|---|---|
| Regimen | Has antineopl Rx | RxNorm CUI | CapeOx | Has antineopl Rx | 194000 |
| Regimen | Has immunosuppr Rx | RxNorm CUI | Dexamethasone monotherapy | Has immunosuppr Rx | 3264 |
| Regimen | Has support med Rx | RxNorm CUI | Carboplatin & Pemetrexed | Has support med Rx | 3264 |
Further explanation of some relationships
Can be followed by
This directed relationship is phrased as an optional because there is always the possibility, even in a pre-defined protocol, that the patient will not go on to receive the second (or third, etc.) part of a treatment protocol.
Can be preceded by
This directed relationship is phrased as an optional because it is contextual; in many treatment contexts it is not necessary that the first treatment occurs before the second. In some treatment contexts the relationship is absolute, e.g., chemotherapy given in the adjuvant setting must by definition be preceded by a surgical procedure. This subtle distinction is not yet captured by the ontology.
Has been compared to
This non-directional relationship is the pairwise comparison of two regimens in a randomized clinical trial. In the most common scenario one regimen is a control arm and the other is experimental arm, although this is not always the case.
Has FDA indication
With very few exceptions, the FDA approves drugs, not regimens. Currently, all of these relationships in HemOnc are between components (drugs) and conditions.
Has reported endpt
For "negative" studies, which we define as those having p>0.10 regardless of the predeclared level of alpha, the reported endpoint is the primary endpoint. For "positive" studies, the reported endpoint is that which is the least surrogate with a p<0.10.
Has route and May have route
Components with only one route of administration are related to that route using "Has route". Conversely, components with multiple routes of administration are related to those routes using "May have route".
Has study type
Right now there is only one defined study class: FDA registration trials. We will plan to expand this in the near future to include details such as phase of study, whether a study was a cooperative group trial, etc.
Was replaced by
This is a special relationship type used to associate current and deprecated concepts. For example, "Imatinib monotherapy, high dose" has been replaced by "Imatinib monotherapy" and the replacement is captured by this relationship.